Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Aptimmune Biologics Inc
Profile last edited on: 1/29/2024      CAGE: 63Y75      UEI: S7N6W8FTTD39

Business Identifier: Prophylactic measures against viral diseases of swine
Year Founded
2010
First Award
2015
Latest Award
2017
Program Status
Inactive
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

60 Hazelwood Drive
Champaign, IL 61820
   (217) 377-8866
   faza@aptimmune.com
   www.aptimmune.com
Location: Single
Congr. District: 13
County: Champaign

Public Profile

Aptimmune Biologics specializes in the development and application of prophylactic measures against viral diseases of swine. Their current focus is bringing into the market effective prophylaxis against Porcine Reproductive and Respiratory Syndrome (PRRS) virus. Aptimmune utilizes novel technologies to create effective vaccines against PRRSV such as the proprietary pig alveolar macrophage cell line ZMAC.

Extent of SBIR involvement

User Avatar
Phase I Awards
1
Phase II Awards
1
Conversion Rate
100.00%
Phase I Dollars
$99,948
Phase II Dollars
$600,000
Total Awarded
$699,948

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2017 2 USDA $699,948
Project Title: A new class of porcine reproductive and respiratory syndrome (PRRS) autogenous vaccine produced in a novel porcine macrophage cell line

Key People / Management

  Aaron Gilbertie -- CEO

  Federico Zuckermann -- Chief Scientific Officer and Founder

  Gabriela Calzada-Nova -- Senior Scientist

  Gary Durack -- Director of Operations

Company News

Jul 09 2015
Aptimmune Biologics Raises $2.75M in Funding
Jul 07 2015
Aptimmune Biologics Raises $2.75 Million of Series A Funding Led by Arsenal Capital Management